Novartis AG (NVSEF)
134.75
-3.02
(-2.19%)
USD |
OTCM |
Sep 14, 16:00
Novartis Price to Book Value : 5.938 for Sept. 14, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 14, 2026 | 5.938 |
| September 11, 2026 | 6.071 |
| September 10, 2026 | 6.079 |
| September 09, 2026 | 6.103 |
| September 08, 2026 | 7.238 |
| September 04, 2026 | 7.238 |
| September 03, 2026 | 7.238 |
| September 02, 2026 | 6.909 |
| September 01, 2026 | 7.143 |
| August 31, 2026 | 6.390 |
| August 28, 2026 | 7.209 |
| August 27, 2026 | 7.209 |
| August 26, 2026 | 7.209 |
| August 25, 2026 | 7.209 |
| August 24, 2026 | 7.209 |
| August 21, 2026 | 6.945 |
| August 20, 2026 | 6.945 |
| August 19, 2026 | 7.050 |
| August 18, 2026 | 6.598 |
| August 17, 2026 | 6.430 |
| August 14, 2026 | 6.958 |
| August 13, 2026 | 6.958 |
| August 12, 2026 | 6.958 |
| August 11, 2026 | 6.958 |
| August 10, 2026 | 6.672 |
| Date | Value |
|---|---|
| August 07, 2026 | 6.694 |
| August 06, 2026 | 6.694 |
| August 05, 2026 | 6.694 |
| August 04, 2026 | 6.694 |
| August 03, 2026 | 6.694 |
| July 31, 2026 | 6.985 |
| July 30, 2026 | 6.985 |
| July 29, 2026 | 6.985 |
| July 28, 2026 | 6.610 |
| July 27, 2026 | 6.610 |
| July 24, 2026 | 6.807 |
| July 23, 2026 | 6.807 |
| July 22, 2026 | 6.742 |
| July 21, 2026 | 6.742 |
| July 20, 2026 | 6.742 |
| July 17, 2026 | 6.693 |
| July 16, 2026 | 6.693 |
| July 15, 2026 | 6.440 |
| July 14, 2026 | 6.556 |
| July 13, 2026 | 6.771 |
| July 10, 2026 | 6.771 |
| July 09, 2026 | 7.050 |
| July 08, 2026 | 7.050 |
| July 07, 2026 | 7.050 |
| July 06, 2026 | 6.973 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Roche Holding AG | -- |
| Addex Therapeutics Ltd. | 0.7931 |
| Oculis Holding AG | 2.286 |
| Sandoz Group AG | -- |
| Galderma Group AG | -- |
Price to Book Value Related Metrics
| PE Ratio | 20.34 |
| PS Ratio | 4.736 |
| Price to Free Cash Flow | 17.09 |
| Price | 134.75 |
| Earnings Yield | 4.92% |
| Market Cap | 246.67B |
| Operating PE Ratio | 16.01 |
| Normalized PE Ratio | 18.95 |